Medicines and treatments 2020 - Consultation response - NICE consultation on health technologies appraisal methodsIn our comment on NICE's proposals for reviewing its health technologies appraisal methods, we made recommendations to enhance and expand its use of patient experience and feedback.2020 - Consultation response - NICE guideline on arranging planned careWe responded to NICE's rapid-turnaround consultation on a draft guideline for arranging planned care in the context of COVID-19. We recommended numerous measures to improve patients' experiences2020 - Consultation response - Evidence based interventionsIn our response to the proposals for a second wave of restrictions to certain treatments, we expressed concern that the methodology remains unproven and relatively lacking in patient input, albeit that many of the proposals are in line with current good practice.2019 - Consultation response - 'Low value' medicines update and further guidanceThis consultation reviewed the 'low value' medicines guidance from 2017, and added some new treatments to its scope. Our response outlined our findings of patients' experiences since the guidance was first introduced.2018 - Consultation response - Evidence based interventionsNHS England proposed to restrict access to some interventions that it deemed poor value for money. Our response highlighted the problems this could cause for patients, and advised NHS England to proceed much more cautiously.2018 - Consultation response - Over the counter medicinesNHS England proposed to issue guidance advising GPs not to issue prescriptions for certain treatments that can be bought over the counter. Our response considers the issue in the context of existing practice in ethical prescribing, and cautions about some of the complexity that the measure may introduce.2017 – Consultation response – 'Low value' medicinesNHS England proposed to issue guidance advising GPs not to prescribe certain medicines in most circumstances. Our response notes that this exercise is almost certainly cost driven, makes specific recommendations about particular medicines, and raises concerns about the development of these proposals, and also future proposals for restricting prescriptions for over-the-counter medicines.